We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Palvella Therapeutics Inc (PVLA) USD0.001

Sell:$4.83 Buy:$12.78 Change: $0.05 (0.42%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$4.83
Buy:$12.78
Change: $0.05 (0.42%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$4.83
Buy:$12.78
Change: $0.05 (0.42%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Palvella Therapeutics, Inc., formerly Pieris Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases. Its lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is in the Phase III SELVA clinical trial in microcystic lymphatic malformations (microcystic LMs) and a Phase II trial in cutaneous venous malformations. It is also engaged in developing treatment for other serious, functionally debilitating skin diseases driven by the overactivation of the mammalian target of rapamycin (mTOR) pathway.

Contact details

Address:
125 Strafford Ave, Suite 360
WAYNE
19087
United States
Telephone:
+1 (484) 2531461
Website:
https://www.pieris.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PVLA
ISIN:
US6979471090
Market cap:
$98.06 million
Shares in issue:
8.32 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Wesley Kaupinen
    President, Chief Executive Officer, Founder, Director
  • Matthew Korenberg
    Chief Financial Officer
  • Kathleen Goin
    Chief Operating Officer
  • Jeffrey Martini
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.